Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Gastrotech signs licensing agreement with Eli Lilly


Copenhagen, 28 January 2008 … Gastrotech Pharma, a biopharmaceutical R&D company with a focus on the medical applications of gastrointestinal hormones, has signed an agreement with Eli Lilly and Company (Indianapolis, USA) to in-license a Lilly compound (now named GTP-010), an analogue of the naturally occurring intestinal hormone GLP-1.

The deal follows positive clinical data from a joint Lilly and Gastrotech proof of concept study to assess pain reduction associated with Irritable Bowel Syndrome (IBS). Gastrotech now plans to develop GTP-010 to treat Irritable Bowel Syndrome (IBS).

Under the terms of the licensing agreement, Gastrotech will receive a global exclusive licence to develop and market GTP-010 for IBS and Functional Dyspepsia. Lilly will take an equity stake in Gastrotech and will receive royalties on sales.

Enda Kenny, Gastrotech Pharma CEO, said: “We believe GTP-010 could have enormous potential in treating IBS, for which there is currently no fully effective treatment. The clinical data collected to date has been highly promising, and we hope to develop GTP-010 as a novel therapy for IBS.”

GTP-010 is an analogue of GLP-1, a naturally occurring intestinal hormone that plays an important physiological role in assisting the human body to maintain appropriate blood sugar levels and modulate gastric motility following meals. GTP-010 has a longer half life than the natural hormone, and is maintained in the circulation during the acute phase of an IBS pain attack. Here it modulates contractile activity and delays gastric emptying before it is cleared by natural mechanisms.

In collaboration with Eli Lilly, Gastrotech has completed an international multicentre Phase IIa proof of concept clinical study in over 100 IBS patients, led by clinical researchers at the Karolinska University Hospital, Stockholm, Sweden. The study met the primary clinical endpoint finding that GTP-010 was able to reduce pain by greater than 50% of the maximum total possible pain relief. The study also met its secondary clinical endpoints including duration of pain and pain relief response, intensity and global impression of treatment.

-ENDS-

About Irritable Bowel Syndrome

Irritable Bowel Syndrome (IBS) is a very common disorder with approximately 75 million sufferers in the developed world. Between 10-20% of the general population exhibit symptoms characterized by bloating, abnormal motility patterns, visceral hypersensitivity, discomfort and pain which can be severe. Current treatments are symptomatic with antispasmodics and low dose tricyclic antidepressants prescribed for frequent or severe pain. The treatment of pain is a significant unmet need in IBS.

About Gastrotech Pharma

Gastrotech Pharma A/S (www.gastrotechpharma.com) is a clinical stage biotechnology company focused on the development of novel treatments for IBS and anorexia/cachexia associated with cancer and other major pathologies.

About Eli Lilly and Company

Eli Lilly and Company (www.lilly.com) is a leading, innovation-driven corporation committed to developing a growing portfolio of best-in-class and first-in-class pharmaceutical products that help people live longer, healthier and more active lives. Lilly products treat depression, schizophrenia, attention-deficit hyperactivity disorder, diabetes, osteoporosis and many other conditions.

Further Information:

Please contact:

Hans T. Schambye, MD PhD
Chairman, Gastrotech Pharma A/S
hs@gastrotechpharma.com
Telephone +45 26373726


Enda Kenny, Ph,D
CEO, Gastrotech Pharma A/S
ek@gastrotechpharma.com
Telephone +45 39179745
Mobile +45 60659639

Adam Michael, Tony Stephenson, Raji Nandipati
College Hill
gastrotech@collegehill.com
Telephone +44 (0)20 7457 2020


Publisher Contact Information:

Gastrotech Pharma A/S
+45 263737
hs@gastrotechpharma.com

Company profile of Gastrotech Pharma A/S
Past press releases of Gastrotech Pharma A/S.

Data


26,231
Tech investments
From our Online Data Service
16,945
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.